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Activating mutations of STAT5B and STAT3 in
lymphomas derived from gd-T or NK cells
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Lymphomas arising from NK or gd-T cells are very aggressive diseases and little is known
regarding their pathogenesis. Here we report frequent activating mutations of STAT3 and
STAT5B in NK/T-cell lymphomas (n¼ 51), gd-T-cell lymphomas (n¼43) and their cell lines
(n¼9) through next generation and/or Sanger sequencing. STAT5B N642H is particularly
frequent in all forms of gd-T-cell lymphomas. STAT3 and STAT5B mutations are associated
with increased phosphorylated protein and a growth advantage to transduced cell lines or
normal NK cells. Growth-promoting activity of the mutants can be partially inhibited by a
JAK1/2 inhibitor. Molecular modelling and surface plasmon resonance measurements of the
N642H mutant indicate a marked increase in binding afﬁnity of the phosphotyrosine-Y699
with the mutant histidine. This is associated with the prolonged persistence of the mutant
phosphoSTAT5B and marked increase of binding to target sites. Our ﬁndings suggest that
JAK-STAT pathway inhibition may represent a therapeutic strategy.
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M
ature NK-cell lymphomas are mostly classiﬁed as
extranodal NK/T-cell lymphomas of nasal type
(NKTCLs)1 in the World Health Organization
classiﬁcation. 70–90% of NKTCLs are of NK cell lineage with
the rest of T-cell origin, most of which are of the gd type. In
current clinical practice, the cases are often lumped together as
NKTCL because of similar clinicopathological features and
management. NKTCL has poor prognosis, particularly in
advanced stage or with extranasal presentation2.
In this study, we investigate the genome-wide driver mutations
in NKTCLs using a combination of RNA sequencing,whole-
exome sequencing (WES) and Sanger sequencing, and identify
activating mutations of STAT3 and STAT5B in the Src homology
2 (SH2) domain. These mutations are also present at a high
frequency (34.9%) in gd-T-cell-derived lymphomas (gd-PTCLs)
and associated with promotion of growth, which can be partially
inhibited by JAK1/2 inhibitors, suggesting a potential therapeutic
option for these patients.
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Figure 1 | Activating STAT3 and STAT5B mutations are frequent in lymphomas of NK or cd-T cell of origin. (a) The diagram shows the type of mutation
analyses performed and the number of tumour samples used for each analysis. The locations of the primers used for PCR and Sanger sequencing of the STAT3
and STAT5B SH2 domains are shown in Supplementary Fig. 1. The location of the mutated nucleotides found in the SH2 domains of STAT3 (b) and STAT5B (c) in
tumour cases (NKTCL, gd-PTCL (PC-gd-PTCL and HS-gd-PTCL) or EATL type II) and cell lines (NK and gd-T cell lines) are shown (not to scale). Mutations
of different tumour cases or cell lines are indicated with different symbols over the SH2 domains, and the disease types to which these symbols refer are shown in
the upper right corner of the panels. Other than A702T, all STAT3 mutations were reported in LGLL by Koskela et al.27 and Jerez et al.26 STAT5B N642H and
Y665F mutations were rarely (B1%) observed in LGLL by Rajala et al.28 (d) The percentages of STAT3 and STAT5B mutations in NKTCL (n¼ 51), gd-PTCL
(n¼ 24) or EATL type II cases (n¼ 19) are shown with piecharts. Apart from the STAT5B Y665F mutation identiﬁed using WES, all SNVs identiﬁed in this
study have been cross-validated on genomic DNAwith Sanger sequencing using both forward and reverse primers. *: two NKTCL tumour samples with WTS data
was re-classiﬁed later as PC-gd-PTCL due to gd-TCR expression. One of these two reclassiﬁed cases is the sample with the STAT3-G618R mutation.
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Results
To identify driver mutations of NKTCLs, whole-transcriptome
sequencing (WTS), exome sequencing or targeted Sanger
sequencing was applied on 53 NKTCL cases (Fig. 1a). First, we
validated the mutations detected from our WTS data that may be
functionally signiﬁcant including the mutations in FAS, TP53,
BRAF, MAP2K1, CREBBP, EP300 and MLL2 genes, by Sanger
sequencing on the corresponding genomic DNA (Supplementary
Table 1). Of note, FAS and TP53 mutations were identiﬁed in
NKTCLs by traditional Sanger sequencing in previous studies3,4.
WTS on 17 cases revealed one STAT3 missense single-nucleotide
variant (SNV) (S614R, G618R and A702T) in each of three cases
(3 of 17, 18%) (Fig. 1b). A STAT5B missense mutation (N642H)
was present in 1 of the 17 (6%) cases (Fig. 1c) and a STAT5B
Y665F mutation was identiﬁed in a WES analysis on a separate
paired NKTCL/normal case. Interestingly, all of the STAT3 and
STAT5B SNVs were located in the SH2 domain, a domain critical
for STAT activation5.
Because all observed SNVs were located in the SH2 domain, we
sequenced the SH2 domains of STAT3 and STAT5B in additional
cases. Sanger sequencing of 35 additional NKTCL cases showed a
STAT3 D661Y mutation and two STAT5B mutations (Y665F and
N642H) in three of these 35 screened cases (Fig. 1b,c). These
analyses yielded a STAT3 and STAT5B mutation frequency of
5.9% in all NKTCL patients screened by WTS, WES and/or
Sanger sequencing (Fig. 1d, left).
RNA-Seq analysis on three NK cell lines revealed an activating
mutation, Y640F, in the SH2 domain of STAT3 in NKYS cells,
which was validated by Sanger sequencing (Fig. 1b). Interestingly,
two out of three additional NK cell lines (SNK6 and YT) showed
STAT3 mutations when screened by Sanger sequencing, raising
the STAT3 mutation frequency to 50% of the six NK cell lines
studied (Fig. 1b). However, Sanger sequencing of the SH2 domain
(ex14–ex18) of STAT5B in these NK cell lines (Supplementary
Fig. 1) did not reveal any STAT5B mutations.
Two recent studies reported the presence of JAK3 A572V,
A573V or V722I mutations in NKTCLs6,7. However, neither
WTS nor hotspot sequencing of 40 NKTCL cases revealed these
SNVs, consistent with a recent report8. The discrepancy may be
due to a variety of factors including the genetic composition of
the populations and different stimuli that initiate and sustain the
initial phase of NK cell proliferation.
Our gene expression proﬁling studies found that NKTCL and
gd-PTCL cases share a very similar proﬁle with each other and
with normal NK cells9, suggesting that these two diseases share
many functional pathways and may use similar oncogenic
mechanisms. Thus, we screened the SH2 domains of STAT3
and STAT5B in 3 gd-T cell lines and 24 gd-PTCL cases (15
primary cutaneous (PC)-gd-PTCL and 9 hepatosplenic (HS)-gd-
PTCL cases). Among the three gd-T cell lines, we observed a
STAT3 Y640F mutation (SNT15) and a STAT3 D661Y mutation
(SNT-8), but no STAT5B mutation was observed (Fig. 1b). We
identiﬁed only a STAT3 Y640F mutation in 1 of the 24 gd-PTCL
cases (Fig. 1b). On the other hand, 8 of 24 (33.3%) cases (four PC
and four HS) showed activating STAT5B mutations in the SH2
domain (Fig. 1c,d).
Enteropathy associated T-cell lymphoma (EATL) is an
aggressive PTCL with higher incidence in the Europe and
USA10. The disease is now classiﬁed into two subtypes: type I is
the classical type with TCR-ab and is associated with celiac
disease and gluten-sensitive enteropathy. EATL type II cases have
been shown to frequently express TCR-gd (B78% in one
study11), and they are not associated with gluten-sensitive
enteropathy. We examined the possibility that STAT3/STAT5B
SH2 domain mutations may play a role in EATL type II
pathogenesis and identiﬁed STAT5B N642H mutations in 7 of 19
cases (36.8%) (Fig. 1c,d). Intriguingly, all mutated EATL
type II cases have gd-T-cell receptor expression (7/16 of
TCR-gd-positive cases) underscoring the signiﬁcance of
STAT5B mutations in the neoplastic transformation of gd-T
cells giving rise to different subtypes of gd-PTCL.
To address whether STAT3 mutations activate the STAT3
pathway, we performed western blotting on six NK cell lines
using STAT3 and phospho-STAT3 (Tyr705) antibodies. High
pY705-STAT3 expression was seen only in mutant cell lines
(Fig. 2a), suggesting that STAT3 is persistently active in the
presence of activating mutations in the SH2 domain. Next, we
transduced the NKYS and YT cell lines, which have the activating
STAT3-Y640F mutation, with empty vector (EV) or STAT3
shRNA with conﬁrmed activity (Supplementary Fig. 2a,b) to
evaluate whether STAT3 silencing inhibits the growth of NK cells.
We quantiﬁed the percentage of GFP positivity of STAT3 shRNA
transduced cells at regular time intervals starting 3 days
post transduction, and observed a markedly reduced percentage
of GFPþ cells compared with vector-only transduced cells,
suggesting a strong negative selection pressure after STAT3
knock-down (Fig. 2b–e). We did not observe a decrease in the
percentage of GFPþ population in STAT3 shRNA transduced
KAI3 cells, which express wild-type (WT) STAT3 (Fig. 2f,g).
STAT3 protein knock-down efﬁciency was B72%, B78% and
Figure 2 | NK cell lines with STAT3 mutations show high pY-STAT3 expression and shRNA-mediated knock-down of STAT3 inhibits NK-cell line
growth. (a) Western blotting was performed on whole-cell lysates (WCL) from six NK cell lines using antibodies to phosphotyrosine (Y705)-STAT3
and STAT3. DHL16 cells, which lack STAT3 activation, were used as a negative control. a-Tubulin was used as a control to ensure equal loading of the
samples. The names of the cell lines used are indicated above the gel image. The type of the corresponding STAT3 mutation is indicated above the
name of the cell lines. ( ): No STAT3 mutation; N.D., not determined. (b) Representative ﬂow cytometric plots showing the percentage of GFPþ cells
3 days (day 0) and 12 days (day 9) post transduction of NKYS cells with EV or STAT3 shRNA after removing IL2 from the culture medium at day 0.
(c) Quantiﬁcation of the percentage of GFPþ cells post transduction of NKYS cells with EV or STAT3 shRNA at regular time intervals. In one experiment,
cells were cultured in the presence of IL2 (5–7 ngml 1) until 3 days (day 0) post transduction and then IL2 was removed from the culture medium.
In the second experiment, IL2 was always included post transduction of NKYS cells. Each data point is representative of two biological replicates.
(d) Representative FACS plots showing the percentage of GFPþ cells of YT cell line transduced with EV or STAT3 shRNA 3 days (day 0) or 15 days
(day 12) post transduction. (e) Quantiﬁcation of the percentage of GFPþ cells by FACS between 3 and 15 days post transduction with EV or STAT3 shRNA.
For 1 week before transduction, YT cells were cultured in the presence of IL2. Three days post transduction (day 0), cells were transferred to medium
lacking IL2. *: Po0.05, Student’s t-test. (f) Representative FACS plots showing the percentage of GFPþ cells in EV or STAT3 shRNA transduced KAI3 cells.
(g) Quantiﬁcation of the percentage of GFPþ cells after transduction of KAI3 cells with EV or STAT3 shRNA. Three days post transduction (day 0),
the percentage of GFPþ cells was determined by ﬂow cytometry, and cells were switched to NK culture medium with reduced IL2 (25 IUml 1). Data
represent means ±s.d. of two biological replicates for panels c,e and g. (h) Western blot images of STAT3 knock-down levels are shown for NKYS,YT
and KAI3 cell lines on STAT3 shRNA transduced, GFPþ sorted cells post transduction with the EV (PLVTH) or STAT3 shRNA (S3S). (i) Quantiﬁcation
of the STAT3 protein knock-down levels after normalization to a-Tubulin using the ImageJ program (http://rsb.info.nih.gov/ij/).
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B39% in NKYS, KAI3 and YT cell lines, respectively (Fig. 2h,i),
which may account for the moderate decrease in growth observed
in YT cells after STAT3 knock-down.
Some of the STAT3/STAT5B mutations have been reported in
other tumours and are likely oncogenic, but other mutations have
not been previously identiﬁed. We used several approaches to
conﬁrm that these mutations are functionally signiﬁcant and
not passenger mutations or uncommon SNPs. We transduced
KAI3 cells, which lack STAT3 or STAT5B mutations, with each
of the STAT3 and STAT5B mutants and determined the % of
GFPþ cells post transduction in regular time intervals. With only
two exceptions, all STAT5B- or STAT3-mutant transduced KAI3
cells showed signiﬁcant progressive positive selection under
limiting IL2 concentrations compared with WT transduced cells
(Fig. 3a,b). STAT3 A702T mutant showed only modest positive
selection when compared with WT transduced cells.
STAT3
DHL16
N.D. – –
M1
41%
STAT3 shRNA
20
40
60
80
100
M1
65%
EV
Day 0
M1
14%
GFP
M1
63.1%
Day 9
–
NKYS
0
20
40
60
80
100
120
EV
STAT3 shRNA
EV (no IL2)
Time (days): 42 7 9
%
 G
FP
+ 
ce
lls
n
o
rm
a
liz
ed
 to
 d
ay
 0
NKYS
M1
95.2%
EV
Day 0 M1
94.4%
STAT3 shRNA
Day 12 M1
97.3%
M1
76.4%
GFP
0
20
40
60
80
100
120
EV
STAT3 shRNA
Time (days): 0 2 6 9 12
Time (days): 0 2 3 6
*
%
 G
FP
+ 
ce
lls
n
o
rm
a
liz
ed
 to
 d
ay
 0
YT
YT
M1
EV
26.2%
Day 0
M1
STAT3 shRNA
7.5%
Day 6
M1
25.4%
M1
7.4%
GFP
KAI3
0
20
40
60
80
100
120
140
EV
STAT3 shRNA
%
 G
FP
+ 
ce
lls
n
o
rm
a
liz
ed
 to
 d
ay
 0
KAI3
Y640F Y640F D661Y
NKYS
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0
0.2
0.4
0.6
0.8
1
1.2
YT KAI3
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7PLVTH PLVTH PLVTH S3SS3SS3S
ST
AT
3 
pr
ot
ei
n 
le
ve
l
n
o
rm
a
liz
ed
 to
 α
-
tu
bu
lin
 
STAT3
PLVTH
YT
PLVTH
NKYS
PLVTH
KAI3
80 kDa
50 kDa
80 KDa
80 KDa
50 KDaα-Tubulin
P-STAT3
(Tyr705)
NKYS KHYG1 YT NK92 SNK6 KAI3
0
100 101 102 103 104
100 101 102 103 104 100 101 102 103 104
100 101 102 103 104
100 101 102 103 104 100 101 102 103 104
100 101 102 103 104 100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104 100 101 102 103 104
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
0
STAT3 shRNA(no IL2)
0
α-Tubulin
S3SS3SS3S
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7025
4 NATURE COMMUNICATIONS | 6:6025 | DOI: 10.1038/ncomms7025 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
Western blot analysis in cell lines clearly demonstrated an
association of STAT3 mutations with increased phosphorylation.
As there are no cell lines with STAT5B mutations, we measured
the phosphorylation of STAT5B proteins in STAT5B-mutant
transduced KAI3 cells and found it to be clearly increased
compared with WT transduced cells (Fig. 3c). Next, we
transduced STAT5B mutants (N642H and I704L) into primary
human NK cells obtained through coculture with engineered
K562 cells, K562-Cl9-mb21, and observed robust promotion of
cell growth in mutant compared with WT transduced cells
(Fig. 4). Intriguingly, the effect of STAT5B N642H was prominent
and the strongest among all mutants tested in KAI3 cells or
normal NK cells.
Next, we evaluated the expression of known STAT5B targets,
IL2Ra (ref. 12), BCL-XL13, BCL2 (ref. 14), MIR155HG (ref. 15)
and HIF2a (ref. 16) in KAI3 cells transduced with STAT5B
mutants (N642H and I704L) and observed signiﬁcantly higher
expression compared with WT or EV transduced cells (Fig. 5a–e),
indicating that the mutants are functionally active and upregulate
oncogenic STAT5B targets, which in part accounts for better
promotion of growth in NK cells. Next, we performed ChIP-q-
PCR on STAT5 binding sites for these genes. Compared with
KAI3 cells transduced with EV or WT STAT5B, a robust
increase in occupancy of STAT5 binding sites were observed in
STAT5B-N642H transduced KAI3 cells (Fig. 5f–j), indicating
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Figure 3 | Ectopic expression of STAT3 or STAT5B mutants promotes growth in KAI3 cells under limiting IL2 concentrations. (a) Quantiﬁcation of the
percentage of GFPþ cells post transduction of KAI3 cells with each STAT3 mutant observed in tumour samples. Transduced cells were cultured in regular
IL2 concentrations for 4 days, then switched to limiting (25 IUml 1) IL2 concentrations. Day 0¼4 days post transduction. Each data point shows the
means±s.d. of two biological replicates. The average values for the % of GFPþ cells at day 0 were 6.9, 3.2, 6.0, 2.8, 4.1, 4.3 and 3.2% for EV, STAT3-WT,
S614R, G618R, Y640F, D661Y or A702T transduced cells, respectively. (b) Quantiﬁcation of the percentage of GFPþ cells post transduction of KAI3 cells
with each STAT5B mutant observed in tumour samples as in a. Means±s.d. of two independent experiments with replicates are shown (n¼4). The
average values for the % of GFPþ cells at day 0 were 4.8, 6.8, 5.9, 5.7, 8.2 and 6.7% for EV, STAT5B-WT, E579K, N642H, Y665F or I704L-mutant
transduced cells, respectively. The percentage of GFPþ cells for each sample is normalized to day 0 in both a,b. (c) P-STAT5(Y699) and STAT5 protein
expression levels in KAI3 cells transduced with STAT5B mutants are shown by western blot. Six days post transduction, the GFPþ population of STAT5B-
mutant transduced cells was isolated by FACS, and then placed into culture medium with limiting (25 IUml 1) concentrations. Whole-cell lysates were
collected 11 days post transduction. One experiment representative of three experiments is shown.
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Figure 4 | Ectopic expression of STAT5B I704L or N642H mutants
promotes growth of primary human NK cells. Quantiﬁcation of the
percentage of GFPþ cells post transduction of primary NK cells with
STAT5B-WT or each of two STAT5B mutants (I704L or N642H) at 3-day
intervals. The percentage of GFPþ cells for each sample is normalized to
day 0. Day 0 indicates 5 days post transduction. The average % of GFPþ
cells at day 0 was 4.6, 4.9 and 4.8% for STAT5B-WT, N642H or I704L
transduced cells, respectively. Data are mean±s.d. of two biological
replicates. Dead cells were stained with 0.5mM of DAPI (Biolegend, cat. no:
422801) to exclude them from quantiﬁcation.
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transduced cells obtained by sorting GFPþ cells 10 days post transduction, and then culturing for 5 days and 2 days in culture medium with regular or
limiting (25 IUml 1) IL2 concentrations, respectively. Means±s.d. of two independent experiments (total combined samples¼4) are shown. *Po0.01
compared with WT, Student’s t-test. ChIP-q-PCR results for known STAT5 binding sites are shown for IL2Ra (f), BCL-XL (g), BCL2 (h), MIR155HG (i) and
HIF2a (j) in EV, STAT5B-WTor STAT5B-N642H transduced KAI3 cells. Data are mean±s.d. of four replicates. STAT5 pull-down normalized to IgG control
as a fold difference compared with STAT5B-WTsample is shown in the y-axis using a log scale. STAT5B consensus sites and their approximate distance to
the TSS sites are indicated.
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that increased STAT5B binding due to the mutation upregulates
the expression of the target genes. Altogether, these results
suggest that the STAT3/STAT5B mutations are oncogenic, driver
mutations.
STAT5B N642H is the most frequent mutation identiﬁed in
gd-PTCLs and appears to have the highest functional potency.
Hence, we sought to determine the molecular basis of the
functional alterations resulting from this mutation through
structural analysis. To mimic homodimerization, we docked a
tyrosine-phosphorylated STAT5B peptide into the WT and
mutant SH2 domains (Fig. 6a–c). Molecular docking showed
that the peptide has a signiﬁcantly higher binding afﬁnity to the
N642H mutant than the WT (Fig. 6d) largely due to the direct
electrostatic interaction of the mutant histidine with the
phosphotyrosine. To conﬁrm these modelling studies, we
produced non-phosphorylated WT and N642H STAT5B (resi-
dues 128 to 717), puriﬁed each to homogeneity, and performed
SPR studies. The WT and mutant STAT5B proteins were coupled
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Figure 6 | Three-dimensional modelling and SPR analysis of the N642H mutant shows stronger afﬁnity for the phosphorylated tyrosine Y699. The
phosphorylated STAT5B peptide involved in homodimerization was docked into the SH2 domain of either WT (a) or N642H (b) STAT5B. The overlay of
these structures (c) shows little difference in the docking poses. In both cases, the N642 or H642 residue was found to be in close proximity to the
phosphorylated tyrosine on the STAT5B peptide (d). The binding energy of these docked structures was calculated for both the WT ( 101.5 kJmol 1) and
N642H ( 125.3 kJmol 1). (e) SPR binding isotherms of phosphopeptide with STAT5B-WT (brown circles) and N642 mutant (blue triangles) of a
representative experiment is shown. Calculated KD values of 14 and 2.9mM for STAT5B-WTand N642H mutant, respectively, are indicated by vertical lines
for the representative experiment. An inset shows the Scatchard plot of the same data. The experiment was repeated for four times, and the means±s.d. of
KD values for WTand N642H are 15.6±1.4 mM and 3.23±0.33mM, respectively. Po0.01 for N642H compared with WT, Student’s t-test. (f) Western blot
image showing P-STAT5(Y699) and STAT5 levels before or after culturing EV, STAT5B-WT or N642H mutant transduced, GFP-sorted YT cells in the
absence (no IL2) or the presence of IL2. YTcells were cultured in the absence of IL2 in each stage of the experiment including 1 week before transduction.
The image is representative of two independent western blots.
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to individual channels of a CM5 SPR chip, and the phosphopep-
tide KAVDG(p)YVKPQI was passed over each channel at
increasing concentrations (0.8 to 100mM) in duplicates. The
binding afﬁnity of the peptide to the WT and N642H mutant was
determined by ﬁtting the equilibrium saturation point as a
function of peptide concentration. The dissociation constants for
the N642H mutant and WT STAT5B on average were 3.2
and 15.6 mM, respectively (Fig. 6e). While these measure-
ments represent a Bﬁvefold difference for the peptide to the
monomeric STAT5B-WT compared with N642H mutant, it is
important to note that phosphoSTAT5B forms a homodimer and
thus there are two phosphotyrosine binding sites. Consequently,
KDimer¼K Monomer1K Monomer2 that translates to a 25-fold
increased association constant for the dimer. Hence, the
homodimeric N642H mutant is substantially more stable than
the WT. This ﬁnding supports the molecular model and the
in vitro cell based assay observations.
To address whether the STAT5B-N642H mutation is asso-
ciated with prolonged STAT5B activation in the presence of acute
JAK-STAT5 pathway activation, we performed western blot on
IL2-activated YT cells in a time-course experiment to evaluate
P-STAT5 expression. The JAK-STAT5 pathway is known to be
inducible in this cell line17. We incubated EV, STAT5B-WT or
N642H-mutant transduced YT cells with IL2 for 30min, and
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evaluated P-STAT5 expression up to 6 h after IL2 withdrawal.
P-STAT5 expression disappeared 1 h after transient IL2
stimulation in EV or STAT5B-WT transduced cells whereas it
persisted for 46 h in N642H transduced cells (Fig. 6f). These
results suggest that the N642H mutation increases afﬁnity of
phospho-STAT5B dimerization and thereby resulting in far more
persistent activation.
We next tested whether a JAK1/2 inhibitor can inhibit cell
growth of STAT5B or STAT3-mutant transduced KAI3 cells.
Most NKCL and gd-PTCL cell lines are still dependent on IL2
which signals mainly through JAK1/2 to activate STAT3 and
STAT5 (refs 18,19). JAK inhibitors are expected to be effective in
interrupting this signalling pathway in cells with WT STAT3 and
STAT5. However, it is unclear whether the inhibitor would
effectively inhibit this pathway at a tolerable dosage in cells
harbouring the mutants. We treated STAT3 or STAT5B mutant
and WT transduced KAI3 cells with 0.5 mM AZD1480, a selective
JAK1/2 inhibitor20. We quantiﬁed viable cells at 72 h post
treatment and observed inhibition of growth in all the mutant
STAT3 and STAT5B transduced cells (Fig. 7a,b). With higher
concentrations of AZD1480, we observed up to 60% inhibition in
STAT5B N642H-mutant transduced cells (Fig. 7c, right),
associated with reduced STAT5 phosphorylation in a dose-
dependent manner (Fig. 7d). Next, we treated YT and NKYS cells,
which have STAT3 mutations, with the JAK1/2 inhibitor and
observed dose-dependent inhibition of cell growth (Fig. 7e).
These data suggest that JAK1/2 inhibitors may have therapeutic
efﬁcacy for NKTCL and gd-PTCL patients with the mutations.
This may have immediate clinical implication as JAK1/2
inhibitors are already approved for myeloproliferative
disorders21,22 so they are available for trials in NKTCL or gd-
PTCL patients while STAT3 and STAT5B inhibitors are still not
clinically available. Further development of small-molecule
inhibitors targeting STAT3 or STAT5B dimerization or DNA
binding may synergize with JAK1/2 inhibitors to improve the
outcome in these diseases with currently dismal prognosis.
Although STAT3 or STAT5B mutations have been reported in
malignancies such as B-cell lymphomas23, angioimmunoblastic
T-cell lymphoma24, CD30þ T-cell lymphoma25, the indolent
LGLL diseases26–28 and recently in T-cell prolymphocytic
leukaemia29, which also included functional characterization of
STAT5 mutations, our study describes prevalent activating
STAT5B and STAT3 mutations in aggressive lymphomas of NK
and gd-T cell of origin. Importantly, we provided strong in vitro
functional data that support an oncogenic role of these mutants
as well as mechanistic insight into how the N642H mutant
acquires enhanced functional activities.
The frequency of activating STAT3 mutations was much higher
in NK (50%) and gd-T cell lines (67%) compared with NKTCL
(5.9%) or gd-PTCL patient samples (8.3%). This suggests that
JAK-STAT3 pathway activation may be more critical in cell
survival independent of stromal components and that conse-
quently the activating mutations are selectively enriched in cell
lines. Intriguingly, STAT5B mutations were far more frequent in
gd-T-cell lymphomas including multiple subtypes: HS, EATL
type II and other mucocutaneous gd-PTCL (34.9%) than
in NKTCL cases (5.9%) suggesting a pivotal role of STAT5B in
gd-PTCL pathogenesis.
Methods
Patient samples and cell lines. The phenotypic characteristics of all NKTCL, dg-
PTCL and EATL type II cases (n¼ 94), NK and dg-T cell lines (n¼ 9) used in this
study are summarized in Supplementary Table 2. Informed consent was obtained
from all patients in accordance with the Declaration of Helsinki, and use of patient
materials and information was approved by the institutional review boards of the
UNMC, West China Hospital Sichuan University, and the participating institutions
of the Tenomic Consortium. KHYG1, KAI3 cell lines were obtained from the
Health Science Research Resource (Osaka, Japan). YT and NK-92 cell lines were
provided by the German Collection of Microorganism and Cell Culture (GCMCC)
(DSMZ, Braunschweig, Germany). Two NK cell lines (SNK6, NKYS) and the gd-T
cell lines (SNT8, SNT13, and SNT15) were obtained from Dr Norio Shimizu
(Tokyo Medical and Dental University). Culture conditions of NK and gd-T cell
lines were as described previously30,31. The DHL16 cell line, purchased from ATCC
(American Type Culture Condition), was cultured in RPMI-1640 (Gibco-
Invitrogen) including 10% FBS; penicillin G (100 unitsml 1) and streptomycin
(100 mgml 1) at 37 C in 5% CO2.
WTS and data analysis. RNA sequencing was performed on resting NK cells, NK
cells activated by IL2 or by K562-Clone9-mb21, 17 NKTCL cases and 3 NK cell
lines. Brieﬂy, 100-bp paired-end libraries were prepared with the TrueSeq RNA
preparation kit (Illumina Inc., San Diego, CA), and high-throughput sequencing
was performed at the UNMC Next Generation Sequencing Core facility and Tufts
University (TUCF) Genomics Core Facility using Illumina Genome Analyzer IIX
or HiSeq 2000 Sequencing systems. FASTQC reports were evaluated for each
sample to evaluate the quality of basic statistics. Two different pipelines were used
to generate the SNVs. The main pipeline used for SNV detection was described
previously32 with the following addition. In addition to the NCBI SNP database
(dbSNP) and 1,000 Genomes project33, three normal NK samples were used to
ﬁlter out the SNPs. The presence of the SNVs was evaluated by visualizing
the SNVs using Integrative Genomics Viewer software (IGV) (http://
www.broadinstitute.org/igv). Finally, the Cosmic release v69 (http://
cancer.sanger.ac.uk/cancergenome/projects/cosmic/) was used to annotate the
variants observed in previous studies. The secondary pipeline used for SNV
detection is as follows: The reads were aligned to the human reference genome
(NCBI GRCh37) using the BWA aligner34 with paired-end (sampe) mode and with
default options. After merging BAM ﬁles, PCR duplications were also removed.
Then, GATK tool35 was used to realign indel-containing reads to the reference
genome. After realignment, GATK UniﬁedGenotyper was used to generate SNP
and indel callsets for 24 (21 malignant and three normal NK samples) RNA-Seq
samples, using a merged BAM ﬁle including all 24 data sets with speciﬁc IDs.
Variant Quality Score Recalibration ﬁlter was applied using the GATK resource
bundle 1.2 to help minimize false positives. Then, ANNOVAR tool36, version 2013-
02-11, was used to annotate the detected SNPs and indels. For gene and ﬁlter
annotation, the April 2012 version of the annotation database (hg191000g2012apr)
and dbSNP version 137 was used. For comparison against the 1,000 Genomes
Project, the data 1000g2012apr was used. Lastly, the SNVs present in three normal
NK samples were ﬁltered out. The basic statistics of RNA-Seq are shown in
Supplementary Table 3. Furthermore, the number of SNVs and their annotations
identiﬁed by the primary RNA-Seq pipeline for 17 NKTCL cases are shown in
Supplementary Fig. 3 and Supplementary Table 4, respectively.
Whole genome ampliﬁcation. Whole genome ampliﬁcation (WGA) of the
NKTCL (n¼ 20) or gd-PTCL (n¼ 4) cases and KAI3 cell line was performed using
the Repli-g kit (Qiagen Inc., Valencia, CA). 50 ng of tissue material was used as a
template for ampliﬁcation. The sensitivity of mutation detection was evaluated by
applying Sanger sequencing on the G to A mutation detected in the intron4/exon5
splice junction of PRDM1 detected previously (Supplementary Fig. 4A)30. Uniform
linear ampliﬁcation of genomic DNA from each NK sample was tested with PCR,
which generatedB3 kb amplicons using KAI3 cell line or NKTCL cases
(Supplementary Fig. 4B,C). In addition, WGA DNA from NKTCL cases was run
on TAE-agarose gels, which showed that WGA DNA contains large fragments
(410 kb) (Supplementary Fig. 4D).
Mutation validation by Sanger sequencing. Sanger sequencing was performed
on DNA from cryopreserved or FFPE tissues, or cDNA if only RNA was available.
Sequencing was focused on the SH2 domain of STAT3 and STAT5B and the
previously reported mutation hotspots for JAK3. The genomic DNA sequences
around the JAK3 A572V, A573V and V722I SNVs was obtained using UCSC
(http://genome.ucsc.edu/) genome browser. PCR primers covering SNVs were
designed with the PrimerQuest software (IDT DNA technologies, Coralville, IA).
The primers were optimized with gradient PCR, and the forward and reverse
primers used for PCR ampliﬁcation of WGA or FFPE gDNA or cDNA samples
were used for Sanger sequencing. Analysis of the sequences was performed using
Vector NTI 10.3.0 (Invitrogen, Carlsbad, CA) and Sequence Scanner Software v1.0
(Applied Biosystems Inc.).The primers used for Sanger sequencing are shown in
Supplementary Table 5.
NK cell isolation and activation for RNA-Seq. Primary human NK cells were
isolated from peripheral blood lymphocytes using a human NK cell isolation kit
(Miltenyi Biotec, Auburn, CA) as described previously37. The purity of NK cells
was evaluated by CD56-APC and CD3-PE double staining, and samples with
495% CD56þCD3 cells were used for RNA-Seq. Resting NK cells were cultured
in the presence of 100 IU of IL2 for 48 h to obtain activated NK cells. Higher levels
of NK cell activation were achieved by coculturing freshly isolated peripheral
blood lymphocytes with engineered K562 cells, K562-Clone9-mb21, as described
in detail before37,38.
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Quantitative reverse transcription PCR (q-RT–PCR). mRNA expression was
determined with q-RT–PCR. RNA isolation and reverse transcription were per-
formed as described previously37,39. Real-time PCR was performed using DyNAmo
HS SYBR Green qPCR Kit (Thermo Scientiﬁc Inc.) with CFX Connect (Bio-Rad,
Hercules, CA) real-time thermocycler. Melting curve analysis was performed to
ensure ampliﬁcation speciﬁcity. The DDCt method was used to calculate the
relative mRNA expression level. RPL13A was used for normalization of gene
expression. Q-RT–PCR primers used in this study are as follows: BCL-XL forward:
50-CTTACCTGAATGACCACCTAGAG-30; BCL-XL reverse: 50- AGGAACCAG
CGGTTGAAG-30; IL2Ra forward: 50-AGCGAGCGCTACCCACTTCTAAAT-30 ;
IL2Ra reverse: 50-AGGGTGGAGAGAGTTCCATACCAT-30 ; BCL2 forward:
50- CATGTGTGTGGAGAGCGT CAA-30; BCL2 reverse: 50-CAGAGACAGCCA
GGAGAAATCA-3. MIR155HG forward: 50-ACGGTTGTGCGAGCAGAGAAT
CTA -30 ; MIR155HG reverse: 50-CTCATCTAAGCCTCACAACAACCT-30 ; HIF2a
forward: 50-GTGCTCCCACGGCCTGTA-30 ; HIF2a reverse: 50-TTGTCACACC
TATGGCATATCACA-30 .
Western blot. Western blot was performed as described previously with the
following modiﬁcations 30. RIPA buffer supplemented with a protease inhibitor
cocktail (Sigma-Aldrich, St Louis, MO) and phosphatase inhibitor cocktails 2 and 3
(Sigma-Aldrich) was used to prepare the whole-cell lysate. Twenty micrograms
protein/sample was used for western blot. BSA (Sigma-Aldrich) was used instead of
non-fat dry milk during blocking. The primary antibodies used for western blotting
are as follows: STAT3 (Cell Signaling Inc., Danvers, MA), STAT5 (3H7) Rabbit
mAb #9358 (Cell Signaling), phospho-STAT5 D47E7 Rabbit mAb # 4322 (Cell
Signaling), phospho-STAT3 (Cell Signaling) and a-Tubulin (Sigma-Aldrich). The
working dilution of a-Tubulin is 1:50,000. The working dilution for all other
antibodies is 1:1,000. Uncropped representative WB images are shown in
Supplementary Fig. 5.
STAT3 shRNA expression in NK cell lines. The lentiviral construct used for
STAT3 knock-down was described previously40. Lentiviral transduction of NK cell
lines or DHL16 was performed following the protocol used for retroviral
transduction37 with the following modiﬁcations: 4 mg PLVTH or PLVTH-S3S was
cotransfected with 2 mg of PMD2G and 2 mg psPAX2 packaging constructs into the
293T cell line to generate lentiviral particles. Transduction was performed once
rather than twice. Transduction efﬁciency was determined with ﬂuorescence-
activated cell sorting (FACS) 3 days post transduction.
Generation and expression of the STAT3 or STAT5B constructs. WT STAT5B
was PCR cloned with the high-ﬁdelity PfuUltra II Fusion HS DNA Polymerase
(Agilent Technologies, Palo Alto, CA) using NK92 cell line cDNA as the template
and then cloned into the multiple cloning site of the pMIG expression vector using
NotI and SalI restriction sites. Similarly, WT STAT3 was PCR cloned into pMIG
from KAI3 cell line cDNA using NotI and SalI sites. Diagnostic mapping and full
insert sequencing was performed. These WT STAT3 or STAT5B constructs were
used as templates for site-directed mutagenesis to generate the STAT3 or STAT5B
mutants used for functional studies as described below apart from the STAT3-
Y640F-pMIG construct, which was PCR cloned with PfuUltra II Fusion HS DNA
Polymerase using the cDNA from NKYS cells, which have the STAT3 Y640F
mutation.
STAT3 or STAT5B SNVs observed in NKTCL, gd-PTCL or EATL type II
samples (patient samples or cell lines) were generated using the Quick-Change
Site-Directed Mutagenesis Kit (Agilent technologies, Santa Clara, CA) according to
the manufacturer’s instructions using WT STAT3 or STAT5B-pMIG vectors
(Supplementary Fig. 6). Diagnostic restriction mapping and full sequencing of the
inserts were performed to ensure the presence of introduced mutation and absence
of another SNV. The primers used for site-directed mutagenesis (SDM) are as
follows: STAT3-S614R-SDM-F: 50-GAAAGCAGCAAAGAAGGACGCGTCACTT
TCACTTGG-30 ; STAT3-S614R-SDM-R: 50-GTGACGCCTCCTTCTTTGCGGCT
TTCACTGAATCTT-30; STAT3-G618R-SDM-F: 50-GAAAGCAGCAAAGAAGG
ACGCGTCACTTTCACTTGG-30; STAT3-G618R-SDM-R: 50-CCAAGTGAAAG
TGACGCGTCCTTCTTTGCTGCTTTC-30 ; STAT3- D661Y-SDM-F: 50-TGGGC
TATAAGATCATGTATGCTACCAATATCCTGG-30 ; STAT3-D661Y-SDM-R:
50-CCAGGATATTGGTAGCATACATGATCTTATAGCCCA-30 ; STAT3-A702T-
SDM-F: 50-AGCTGACCCAGGTAGCACTGCCCCATACCTGAAG-30 ; STAT3-
A702T-SDM-R: 50-CTTCAGGTATGGGGCAGTGCTACCTGGGTCAGCT-30 ;
STAT5B-E579K-SDM-F: 50-GGTTTGACGGTGTGATGAAAGTGTTAAAAAAA
CATC-30; STAT5B-E579K-SDM-R: 50-GATGTTTTTTTAACACTTTCATCACA
CCGTCAAACC-30 ; STAT5B-N642H-SDM-F: 50-GGAAAGAATGTTTTGGCAT
CTGATGCCTTTTACC-30 ; STAT5B-N642H-SDM-R: 50-GGTAAAAGGCATCA
GATGCCAAAACATTCTTTCC-30 ; STAT5B-Y665F-SDM-F: 50-GCTTGGGAGA
CTTGAATTTCCTTATCTACGTGTTTC-30 ; STAT5B-Y665F-SDM-R: 50-GAAA
CACGTAGATAAGGAAATTCAAGTCTCCCAAGC-30 ; STAT5B-I704L-SDM-F:
50-GGATACGTGAAGCCACAGCTCAAGCAAGTGGTCCCTG-30 ; STAT5B-
I704L-SDM-R: 50-CAGGGACCACTTGCTTGAGCTGTGGCTTCACGTATCC-30 .
Retroviral transduction of NK cell lines was performed as previously
described39 with the following modiﬁcations: 4 mg of pMIG or pMIG vectors
expressing WT or mutated STAT3/STAT5B gene was cotransfected with 4 mg of
the packaging construct PCL-Ampho into the 293T cell line. A single transduction
was performed. Transduction efﬁciency was determined with ﬂow cytometry on
GFPþ cells 2–4 days post transduction. KAI3 cells were cultured in the presence of
20% FBS to increase transduction efﬁciency.
Conditioning primary NK cells for retroviral transduction. Primary human NK
cells were expanded using a special ex vivo system that involves coculturing pri-
mary human NK cells with an engineered NK cell target, K562-Cl9-mb21, which
activates and induces proliferation of NK cells robustly as described before37,39.
The expansion procedure is described brieﬂy as follows: First, primary human NK
cells were isolated by negative selection using EasySepHuman NK cell enrichment
kit (Stemcell technologies,Vancouver,Canada). Then, primary NK cells were
admixed in a 1:2 ratio with 100 Gr irradiated K562-Cl9-mb21cells, which express
CD86, 4-1BBL and mIL21 on their surface, and cultured in NK cell expansion
medium38. Cells were spun down at 400g for 5min, and the culture medium was
renewed every 3 days with fresh culture medium, keeping the cell density at
250,000 cells per ml after every subculture. Nine days after coculture started, cells
were immunostained with CD56-PE (Biolegend, San Diego, CA) and CD3-FITC
(Biolegend) antibodies to determine the NK cell purity by FACS. On the same day
purity was determined, primary NK cells were transduced with WT or mutant
STAT5B retroviral constructs.
Determination of positive/negative selection of transduced cells. STAT3
shRNA or STAT3/STAT5B mutant transduced NK cell lines were tracked by
quantiﬁcation of the GFPþ cells using ﬂow cytometry after transduction to
determine negative or positive selection of cells, respectively, because GFP was used
as the marker of transduction. The following ﬂow cytometers were used for
determination of GFPþ cells: FACS Calibure (BD Biosciences), BD LSRFortessa
(BD Biosciences) and Gallious (Beckman Coulter Inc.) Autoﬂuorescent cells, which
emit both green and orange, represent false positive, untransduced cells, were
ﬁltered out through proper gating. During quantiﬁcation of GFPþ cells in trans-
duced primary NK cells, dead cells were labelled and ﬁltered out by staining the
cells with 0.5 ugml 1 DAPI (Biolegend, cat.no: 422801) for 10min before ﬂow
cytometry.
ChIP-q-PCR. Ten million cells isolated from GFP-sorted, EV, STAT5B-WT or
N642H-mutant transduced KAI3 cells were used for chromatin immunoprecipi-
tation using ChIP-IT Express Enzymatic (Active Motif, Carlsbad, CA) following
the manufacturer’s recommendations.The procedure is described brieﬂy as follows:
the enzymatic digestion time was optimized as 10min based on the TAE-agarose
gel image. Cells (10*106) per sample were ﬁxed with 1% formaldehyde. After
enzymatic fragmentation, STAT5 (3H7) Rabbit mAb #9358 (Cell Signaling Inc.)
and rabbit anti-IgG Control (Abcam Inc., Cambridge, MA) antibodies were used
side-by-side for immunoprecipitations. Twenty micrograms of chromatin/reaction
was immunoprecipitated using dilutions of STAT5 or IgG antibody based on
manufacturers’ recommendations. After elution of DNA, reversal of DNA cross-
links, and proteinase K treatment, q-PCR was performed using 2 ml of gDNA in
replicate. STAT5 immunoprecipated DNA levels were normalized to the levels of
IgG immunoprecipitated DNA for each sample. STAT5 binding sites reported
before for IL2Ra (ref. 12), BCL2 (ref. 14), BCL-XL (ref. 12), HIF2a (ref. 16) and
MIR155HG (ref. 15) were evaluated. The sequences of ChIP-q-PCR primers used
in this study is as follows: IL2Ra-ChIP-q-PCR-F: 50-AAAACCAATTTCTTGGGA
TGG-30 ; IL2Ra-ChIP-q-PCR-R: 50 :AGGGGAAATTCCGTTGAGTT-30 ; BCL2
ChIP-q-PCR-F: 50-ACTTTACATTTCTGTTGTGTTTACAGC-30 , BCL2 ChIP-q-
PCR-R: 50-ATTCATACATATGCACACGCACA-30 ; BCL-XL ChIP-q-PCR F:
50-AATTCAGCTGCCAGCCTCT-30, BCL-XL ChIP-q-PCR R: 50-CAACCGCTT
CCTTTTCTGAG-30 , HIF2a (EPAS1) ChIP-q-PCR F: 50-CAGTGTCCTGAGACT
GTATG-30 , HIF2a (EPAS1) ChIP-q-PCR R: 50-CTGTCAGACCCGAAAAGA-30 ,
MIR155HG ChIP-q-PCR F: 50-GAAAGGGAAAGGGGAAAACA-30 , MIR155HG
ChIP-q-PCR R: 50-CGAACGTGCGACCCTTTTAT-30 .
AZD1480 treatment of mutant STAT3- or STAT5B-transduced KAI3 cells. In
all, 25,000 KAI3 cells were seeded in 2ml inside 24-well plates in replicates or
triplicates and treated with 0, 0.5, 1 or 2 mM of AZD1480 for 72 h. Seventy-two
hours post treatment, the total viable cell number in each well was quantiﬁed using
a Vi-cell XR Cell Viability Analyzer (Beckman Coulter Inc.) according to the
manufacturer’s instructions. Total cell number in each treated sample was
normalized to that of the untreated control cells.
Three-dimensional structural modelling of the STAT5B-N642H mutant. The
STAT5B structure was modelled on the available STAT5A structure (PDB ID:
1Y1U) using the program MODELLER41. There was little difference in the SH2
domains as these two proteins have extremely similar primary sequences. Then, the
modelled STAT5B SH2 domain was compared with other proteins containing SH2
domains that had been cocrystallized with peptides (v-SRC, GRB2, SH2B, NCK2)
which showed the site of the N642H was directly located in the key binding pocket
of the phosphorylated tyrosine. Phosphorylated self-peptide (STAT5B: VDG-PTR-
VKPQ) was docked into the SH2 domain of WT-STAT5B or N642H STAT5B,
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7025
10 NATURE COMMUNICATIONS | 6:6025 | DOI: 10.1038/ncomms7025 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
respectively. Protein–protein docking was done with the FFT-based docking tool
ClusPro42 on a dedicated server. Key binding residues (STAT5B: R618, S620, N621,
K600, N642) were speciﬁed based on previous peptide–SH2 domains cocrystallized
structures (PDB ID: 2HDX, 1SHA, 2CIA, 1TZE). The best docking results were
selected based on an electrostatically favoured scoring function. ClusPro docking
server ﬁrst clustered 1,000 ligand positions with the lowest energy score according
to the 9 angstrom C-alpha RMSD radius and then ranked the best model. With the
energy-minimized protein-peptide docked model, the binding energy of the
complex was calculated with MolDock43.
Surface plasmon resonance binding assay. For surface plasmon resonance,
WT and N642H-mutant STAT5B (residues between 128aa-717aa, NM_012448)
was PCR cloned into the SMT3-pET28bþ plasmid using the BamHI and
XhoI cloning sites. BclI instead of BamHI restriction site was used in the forward
primer to prevent digestion of STAT5B due to the presence of an internal
BamHI site. A TGA stop codon was included in the reverse primer so that C-term
His was not expressed. High-ﬁdelity PfuUltra II Fusion HS DNA Polymerase
(Agilent Technologies, Palo Alto, CA) was used to amplify STAT5B insert
from STAT5B-WT-pMIG vector. Diagnostic mapping and Sanger sequencing
of the inserts and the integration sites were performed to check the quality of
the clones.
WT and mutant STAT5B expression was performed as follows: Plasmid DNA
was transformed into BL21 (DE3) Codon Plus RIL competent cells (Agilent
Technologies) and plated on LB agar plates with chloramphenicol (Cam) and
kanamycin (Kan). Single colonies were selected and grown in LB media with Cam
and Kan overnight at 37 C. Overnight culture of 6 6ml was used to inoculate
6 1 l LB media with Kan and Cam. Cultures were grown at 37 C to an optical
density of 0.6, then ﬂasks were moved to a precooled shaker at 18 C. Cultures were
grown at 18 C until they reached an optical density between 0.9and 1.1. Protein
expression was induced with a ﬁnal concentration of 500 mM isopropyl-b-D-
thiogalactoside, and cells were allowed to grow 16–20 h at 18 C with continued
shaking. Cells were harvested by centrifugation, resuspended in PBS and frozen at
 20 C until puriﬁcation.
His6-SMT fusions of both WT and N642 mutant STAT5B were puriﬁed as
previously published44. Brieﬂy, cells were thawed and lysed by French pressure cell
with DNase I and PMSF. Lysates were clariﬁed by centrifugation and ﬁltration.
Lysates were applied to Ni-NTA (Thermo Scientiﬁc HisPur) and washed with a
PBS/imidazole gradient. Eluted protein was dialysed overnight at 4 C into PBS in
the presence of His6-ULP1 enzyme with 1mM dithiothreitol. The dialysed protein
was incubated with Ni-NTA beads before concentration to remove uncleaved
material, His6-SMT and His6-ULP1. The unbound material was then loaded onto
the preparative grade superdex G200 gel ﬁltration column (GE lifesciences) and
exchanged into 50mM Tris pH 8.0, 100mM NaCl, 1mM EDTA, and 1mM
dithiothreitol on column. The peak eluting at B190ml was concentrated,
aliquotted into small volumes, and stored at  80 C.
Surface plasmon resonance studies were carried out with the GE Lifesciences
Biacore T100 instrument at 25 C. STAT5B-WT and N642H variant ligands were
thawed and extensively dialysed into HBS-N buffer (GE Lifesciences). Protein
samples of 50mgml 1 were made by diluting the dialysed stock samples into
acetate pH 5.0 buffer immediately before immobilization. Both STAT5B proteins
were coupled using EDC/NHS amine coupling chemistry with ﬁnal immobilization
levels of 5345.6 RU for WT and 5433.9 RU for N642H variant. Reference channels
received a blank amine coupling protocol. The analyte, phosphopeptide
(KAVDG(p)YVKPQI) (Anaspec, Fremont, CA) was prepared by dissolution in
water and extensive dialysis into water. The peptide stock solution was stored at
4 C before analysis. Two-fold dilutions of the phosphopeptide stock were prepared
in HBS-EPþ (GE lifesciences) ranging from 100 to 0.78 mM immediately before
analysis. Peptide samples were ﬂowed over the immobilized ligand at a rate of
30ml min 1 with each concentration being run in duplicate. HBS-EPþ was used
both as running and regeneration buffer. KD values were calculated using
BiaEvaluation software (Biacore AS, Uppsala, Sweeden) by ﬁtting the binding
isotherms to a 1:1 Langmuir model.
Statistical analysis. Two-tailed unpaired t-test was applied using Microsoft Ofﬁce
Excel (Microsoft, Redmond, WA). Po0.05 was considered statistically signiﬁcant.
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